Cardiac dysfunction and prolonged hemodynamic deterioration after implantable cardioverter-defibrillator shock in

Norihisa Toh1, Nobuhiro Nishii, Kazufumi Nakamura

  • 1Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. nori-t@fd5.so-net.ne.jp

Insights

Implantable cardioverter-defibrillator shocks temporarily reduce cardiac function, particularly in patients with systolic dysfunction. However, no significant tissue damage was observed following the procedure.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Cardiac Physiology

Background:

  • Investigating acute effects of implantable cardioverter-defibrillator (ICD) shock on cardiac function and hemodynamics.
  • Assessing the impact in relation to left ventricular systolic function.

Purpose of the Study:

  • To evaluate the immediate consequences of ICD shock on myocardial function and hemodynamics.
  • To compare these effects between patients with preserved and reduced left ventricular ejection fraction (LVEF).

Main Methods:

  • Studied 50 patients undergoing ICD implantation and defibrillation threshold (DFT) testing.
  • Measured cardiac biomarkers and assessed left ventricular relaxation using echocardiography.
  • Monitored hemodynamic parameters and LVEF before and after DFT testing.

Main Results:

  • No significant changes in cardiac biomarkers were observed.
  • LVEF transiently decreased in patients with reduced LVEF post-shock, recovering within 4 hours.
  • Left ventricular relaxation was impaired transiently in both groups post-shock.

Conclusions:

  • ICD shock transiently impairs cardiac function and hemodynamics, especially in patients with systolic dysfunction.
  • Significant myocardial tissue injury was not observed after ICD shock.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...